Source: Benzinga Feeds
DUBLIN , Feb. 21, 2020 /PRNewswire/ — The “Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030” report has been added to ResearchAndMarkets.com’s offering. The Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030 report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. The report also features the likely distribution of the current and forecasted opportunity across [A] key therapeutic areas (genetic disorders, hematological malignancies, autoimmune disorders, infectious diseases, inflammatory disorders, eye disorders and skin disorders), [B] different mechanisms of action (T-cell retargeting / activation, cytokines retargeting / neutralization, dual ligands blocking and others), [C] key targets (CD3 x CD19, CD30 x CD16A, Factor IXa x Factor X, IL-13 x IL-4, IL-17A x Albumin, IL-17A x IL-17F, IL-1 x IL-1, Psl x PcrV, TNF- x HSA and VEGF-A x ANG-2), [D] type of antibody formats (asymmetric, fragments, symmetric and others), [E] key players (AbbVie, Affibody, Affimed, Amgen, AstraZeneca, Merck, Roche, Sanofi and Taisho Pharmaceutical) and [F] key geographical regions ( North America , Europe and Asia Pacific ).